281 related articles for article (PubMed ID: 12192052)
1. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function.
So CW; Cleary ML
Mol Cell Biol; 2002 Sep; 22(18):6542-52. PubMed ID: 12192052
[TBL] [Abstract][Full Text] [Related]
2. Common mechanism for oncogenic activation of MLL by forkhead family proteins.
So CW; Cleary ML
Blood; 2003 Jan; 101(2):633-9. PubMed ID: 12393557
[TBL] [Abstract][Full Text] [Related]
3. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10.
DiMartino JF; Ayton PM; Chen EH; Naftzger CC; Young BD; Cleary ML
Blood; 2002 May; 99(10):3780-5. PubMed ID: 11986236
[TBL] [Abstract][Full Text] [Related]
4. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.
DiMartino JF; Miller T; Ayton PM; Landewe T; Hess JL; Cleary ML; Shilatifard A
Blood; 2000 Dec; 96(12):3887-93. PubMed ID: 11090074
[TBL] [Abstract][Full Text] [Related]
5. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias.
So CW; Lin M; Ayton PM; Chen EH; Cleary ML
Cancer Cell; 2003 Aug; 4(2):99-110. PubMed ID: 12957285
[TBL] [Abstract][Full Text] [Related]
6. Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23).
Borkhardt A; Repp R; Haas OA; Leis T; Harbott J; Kreuder J; Hammermann J; Henn T; Lampert F
Oncogene; 1997 Jan; 14(2):195-202. PubMed ID: 9010221
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins.
Ayton PM; Cleary ML
Oncogene; 2001 Sep; 20(40):5695-707. PubMed ID: 11607819
[TBL] [Abstract][Full Text] [Related]
8. Cooperativity in transcription factor binding to the coactivator CREB-binding protein (CBP). The mixed lineage leukemia protein (MLL) activation domain binds to an allosteric site on the KIX domain.
Goto NK; Zor T; Martinez-Yamout M; Dyson HJ; Wright PE
J Biol Chem; 2002 Nov; 277(45):43168-74. PubMed ID: 12205094
[TBL] [Abstract][Full Text] [Related]
9. The small oligomerization domain of gephyrin converts MLL to an oncogene.
Eguchi M; Eguchi-Ishimae M; Greaves M
Blood; 2004 May; 103(10):3876-82. PubMed ID: 14751928
[TBL] [Abstract][Full Text] [Related]
10. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis.
Ono R; Nakajima H; Ozaki K; Kumagai H; Kawashima T; Taki T; Kitamura T; Hayashi Y; Nosaka T
J Clin Invest; 2005 Apr; 115(4):919-29. PubMed ID: 15761502
[TBL] [Abstract][Full Text] [Related]
11. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis.
Luo RT; Lavau C; Du C; Simone F; Polak PE; Kawamata S; Thirman MJ
Mol Cell Biol; 2001 Aug; 21(16):5678-87. PubMed ID: 11463848
[TBL] [Abstract][Full Text] [Related]
12. Structures of KIX domain of CBP in complex with two FOXO3a transactivation domains reveal promiscuity and plasticity in coactivator recruitment.
Wang F; Marshall CB; Yamamoto K; Li GY; Gasmi-Seabrook GM; Okada H; Mak TW; Ikura M
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6078-83. PubMed ID: 22474372
[TBL] [Abstract][Full Text] [Related]
13. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia.
Lavau C; Du C; Thirman M; Zeleznik-Le N
EMBO J; 2000 Sep; 19(17):4655-64. PubMed ID: 10970858
[TBL] [Abstract][Full Text] [Related]
14. Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein.
Ayton PM; Chen EH; Cleary ML
Mol Cell Biol; 2004 Dec; 24(23):10470-8. PubMed ID: 15542854
[TBL] [Abstract][Full Text] [Related]
15. MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein.
Xia ZB; Anderson M; Diaz MO; Zeleznik-Le NJ
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8342-7. PubMed ID: 12829790
[TBL] [Abstract][Full Text] [Related]
16. The FEL (AF-4) protein donates transcriptional activation sequences to Hrx-Fel fusion proteins in leukemias containing T(4;11)(Q21;Q23) chromosomal translocations.
Morrissey JJ; Raney S; Cleary ML
Leuk Res; 1997 Oct; 21(10):911-7. PubMed ID: 9403001
[TBL] [Abstract][Full Text] [Related]
17. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9.
Ayton PM; Cleary ML
Genes Dev; 2003 Sep; 17(18):2298-307. PubMed ID: 12952893
[TBL] [Abstract][Full Text] [Related]
18. The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation.
Birke M; Schreiner S; García-Cuéllar MP; Mahr K; Titgemeyer F; Slany RK
Nucleic Acids Res; 2002 Feb; 30(4):958-65. PubMed ID: 11842107
[TBL] [Abstract][Full Text] [Related]
19. LAF-4 encodes a lymphoid nuclear protein with transactivation potential that is homologous to AF-4, the gene fused to MLL in t(4;11) leukemias.
Ma C; Staudt LM
Blood; 1996 Jan; 87(2):734-45. PubMed ID: 8555498
[TBL] [Abstract][Full Text] [Related]
20. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX.
Slany RK; Lavau C; Cleary ML
Mol Cell Biol; 1998 Jan; 18(1):122-9. PubMed ID: 9418860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
